<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04013477</url>
  </required_header>
  <id_info>
    <org_study_id>DA5207_ADK_Ia</org_study_id>
    <nct_id>NCT04013477</nct_id>
  </id_info>
  <brief_title>Single-ascending Dose Phase 1 Clinical Trial to Evaluate the Safety and PK of DA-5207 TDS in Healthy Adults</brief_title>
  <official_title>A Single-blinded, Placebo- and Active-controlled, Parallel, Single-ascending Dose Phase 1 Clinical Trial to Evaluate the Safety and Pharmacokinetics of DA-5207 Transdermal Delivery System in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A ST Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A ST Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-blinded, placebo- and active-controlled, parallel, single-ascending dose phase 1
      clinical trial to evaluate the safety and pharmacokinetics of DA-5207 transdermal delivery
      system in healthy adults
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2019</start_date>
  <completion_date type="Anticipated">October 18, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>patch : 21days, oral : 11days</time_frame>
    <description>area under the concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>patch : 21days, oral : 11days</time_frame>
    <description>maximum serum concentration</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug : DA-5207 80mg/40cm²
placebo : 40cm²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug : DA-5207 120mg/60cm²
placebo : 60cm²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>drug : DA-5207 160mg/80cm²
placebo : 80cm²</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>drug : Aricept</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DA-5207</intervention_name>
    <description>DA-5207 Transdermal Delivery System</description>
    <arm_group_label>Cohort1</arm_group_label>
    <arm_group_label>Cohort2</arm_group_label>
    <arm_group_label>Cohort3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Donepezil Hydrochloride</intervention_name>
    <description>donepezil HCl 10mg QD</description>
    <arm_group_label>Cohort4</arm_group_label>
    <other_name>Aricept</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Health Male Volunteers (Age : 19~55 years)

          -  Body Weight : Male≥55kg, Female≥50kg

          -  18.5≤BMI&lt;25.0

        Exclusion Criteria:

          -  Galactose intolerance, Lapp lactase deficiency, Glucose-galactose malabsorption

          -  Allergy or Drug hypersensitivity

          -  Clinically significant Medical History

          -  AST, ALT &gt; Upper Normal Range*1.25, eGFR&lt;60mL/min/1.73m²

          -  Heavy alcohol intake (more than 210g/week)

          -  Heavy smoker (more than 10 cigarettes/day)

          -  Heavy caffeine intake
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Min soo Park, M.D., Ph.D.</last_name>
    <phone>+82-2-2228-0455</phone>
    <email>minspark@yuhs.ac</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trials Center, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min soo Park, M.D., Ph.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2019</study_first_posted>
  <last_update_submitted>July 8, 2019</last_update_submitted>
  <last_update_submitted_qc>July 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Donepezil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

